التفاصيل البيبلوغرافية
| العنوان: |
Targeting the Neuropilin-1 receptor with Ovatodiolide and progress in using periodontal ligament organoids for COVID-19 research and therapy. |
| المؤلفون: |
Hsieh, Ming-Shou1,2 (AUTHOR), Chen, Ming-Yao1,3,4,5 (AUTHOR), Chang, Yu-Sheng6,7 (AUTHOR), Huang, Chin-Sheng1,2 (AUTHOR), Hsu, Tung-Nien1,2 (AUTHOR), Huang, Mao-Suan1,2 (AUTHOR), Yeh, Chi-Tai1,8,9,10 (AUTHOR) ctyeh@s.tmu.edu.tw, Tzeng, Yew-Min1,11 (AUTHOR) ymtzeng@nttu.edu.tw |
| المصدر: |
Life Sciences. Aug2024, Vol. 351, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*PERIODONTAL ligament, *COVID-19 treatment, *CELL communication, *STEM cells, *SARS-CoV-2, *LIGAMENTS, *ALVEOLAR process |
| مستخلص: |
The discovery of SARS-CoV-2 RNA in the periodontal tissues of patients who tested positive for COVID-19, 24 days post the initial symptom onset, indicates the oral cavity could serve as a viral reservoir. This research aims to investigate the antiviral capabilities of Ovatodiolide, introducing a novel periodontal ligament organoid model for the study of SARS-CoV-2. We have successfully established a reliable and expandable organoid culture from the human periodontal ligament, showcasing characteristics typical of epithelial stem cells. This organoid model enables us to delve into the lesser-known aspects of dental epithelial stem cell biology and their interactions with viruses and oral tissues. We conducted a series of in vitro and ex vivo studies to examine the inhibitory impacts of Ova on SARS-CoV-2. Our findings indicate that Ovatodiolide molecules can bind effectively to the NRP1 active domain. Our study identifies potential interaction sites for Ovatodiolide (OVA) within the b1 domain of the NRP1 receptor. We generated point mutations at this site, resulting in three variants: Y25A, T44A, and a double mutation Y25A/T44A. While these mutations did not alter the binding activity of the spike protein, they did impact the concentration of OVA required for inhibition. The inhibitory concentrations for these variants are 15 μM for Y25A, 15.2 μM for T44A, and 25 μM for the double mutant Y25A/T44A. In addition, in vitro inhibition experiments demonstrate that the EC50 of Ova against the main protease (Mpro) of the SARS-CoV-2 virus is 7.316 μM. Our in vitro studies and the use of the periodontal ligament organoid model highlight Ovatodiolide's potential as a small molecule therapeutic agent that impedes the virus's ability to bind to the Neuropilin-1 receptor on host cells. The research uncovers various pathways and biochemical strategies through which Ovatodiolide may function as an effective antiviral small molecule drug. [Display omitted] • Ovatodiolide as a potential drug inhibiting SARS-CoV- 2 infiltration of host cells. • Ovatodiolide inhibits the binding of SARS-CoV-2 spike S1 to human NRP1 receptor. • Ovatodiolide blocks the interaction between SARS-CoV-2 S1 and the human neuropilin-1 (NRP1) receptor Ex vivo. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |